Endo Inks US Pact For Osteoarthritis Pain Injectable
TLC BioSciences has entered a commercialization agreement with Endo International plc (NASDAQ:ENDP) for the U.S. rights of TLC599, a proprietary BioSeizer sustained-release injectable in Phase 3 development for osteoarthritis pain. Under the agreement signed with Endo's subsidiary Endo Ventures Limited (EVL), TLC will primarily be responsible for developing the product, and EVL for obtaining regulatory…
Benzinga ·